HOME >> MEDICINE >> NEWS
UCLA studies experimental cancer drug

Men with high-risk prostate cancer who are candidates for surgery are being sought to test a molecularly targeted experimental drug that may interrupt the signal that is driving their cancer and keep the disease from recurring.

The early-phase clinical trial is based on basic research discoveries made in Jonsson Cancer Center laboratories. UCLA researchers have successfully tested the drug in laboratory and animal models. They hope to translate that benefit into patients in the clinic, said Dr. Charles Sawyers, co-principal investigator for the study and the Jonsson Cancer Center scientist whose basic research resulted in the clinical trial.

UCLA laboratory studies have shown that some patients with prostate cancer have lost PTEN, a tumor-suppressor gene. In some patients who have lost PTEN, a gene called mTOR located downstream in the cell-signaling pathway gets turned on and may be driving the cancer. Sawyers, along with co-principal investigator Dr. Robert Reiter, will test a drug called CCI779, which they believe targets mTOR.

"We discovered that tumors missing PTEN seem to be very responsive to CCI779, and it's very clear at a molecular biology level why," Sawyers said. "When you've lost PTEN, mTOR activity gets turned up and tumors become dependent on it for their growth. So a drug that inhibits mTOR should impact the tumor cells but have no effect on the normal cells."

Armed with his laboratory discoveries, Sawyers proposed the prostate cancer study to Wyeth Pharmaceuticals, and the clinical trial was designed. UCLA's Jonsson Cancer Center is the only West Coast site offering this study. Other sites participating include MD Anderson Cancer Center in Texas and Fox Chase Cancer Center in Philadelphia, Sawyers said.

Because CCI779 targets only what is broken in the cancer cell, it is expected to cause very few side effects, Sawyers said.

UCLA researchers are seeking study volunteers with newly diagnosed prostate ca
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
4-Dec-2003


Page: 1 2

Related medicine news :

1. New studies suggest airborne SARS transmission is possible
2. New studies show mixed results on epilepsy drugs and birth defects
3. Brain imaging studies investigate pain reduction by hypnosis
4. Impact of scientific advances on drug studies and membrane research to be explored
5. Two studies find evidence that sunlight may have beneficial influence on cancer
6. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
7. Animal studies show stem cells might make biological pacemaker
8. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find
9. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
10. Gender and sex hormones affect the brains pain response and more, according to new studies
11. Analysis of tamoxifen studies reveals slight increase of stroke risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCLA studies experimental cancer drug

(Date:7/6/2015)... ... 06, 2015 , ... University of Pittsburgh Cancer Institute (UPCI) scientists ... to reflect newly available tests that better incorporate personalized medicine into diagnosing the condition. ... cancer tests is published in the July issue of the scientific journal Thyroid ...
(Date:7/6/2015)... Branford, Connecticut (PRWEB) , ... July 06, 2015 ... ... Aesthetic Medical Practice & Medical Spa industries, announces the return of its complimentary ... the Acara team of aesthetic medical business leaders creates success for their clients ...
(Date:7/6/2015)... BC (PRWEB) , ... July 06, 2015 , ... Olive ... received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of ... is a very exciting field to be practicing in. The technology is changing so ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN patient ... cancer. , “Receiving a cancer diagnosis is often the most traumatic experience of ...
(Date:7/6/2015)... ... , ... MD Now, the leading and fastest-growing urgent care provider in Florida, ... will serve residents and visitors in the Cutler Bay area, giving them convenient access ... location, the new facility will be the fourth to serve Miami-Dade County. Located at ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3
(Date:7/6/2015)... , July 6, 2015 Moerae Matrix, ... novel therapeutics that target inflammation and fibrosis, today ... M.D., PhD, as Chief Medical Officer. ... development strategy and programs, which include a pipeline ... and fibrotic conditions.  Bill is an accomplished strategist ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SUNNYVALE, Calif. , July 6, 2015   ... will report financial results for its 2015 second quarter ... after the close of the market. The ... Pacific Time on Thursday, July 23, 2015, to discuss ... Cepheid,s website at http://ir.cepheid.com at least 15 ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
Cached News: